Loading
Serous endometrial cancers often overproduce HER2. Enhertu already works in them; testing HER2 in every p53-abnormal tumour and using the ADC earlier could change outcomes for the worst subtype.
Serous endometrial carcinomas, which fall in the p53-abnormal molecular class, frequently amplify HER2, and this idea proposes testing HER2 in every p53-abnormal tumour and using trastuzumab deruxtecan earlier. T-DXd produced a high response rate in HER2 IHC 3+ endometrial cancer in DESTINY-PanTumor02, leading to tumour-agnostic approval, and trastuzumab with chemotherapy improved progression-free survival in a randomised phase 2 reported by Fader in 2018. The rationale is strong single-agent activity, a defined biomarker, and a subtype with the shortest survival that gains least from immunotherapy. The proposed test is a randomised phase 3 of first-line chemo-immunotherapy with or without T-DXd in HER2-positive p53abn disease, at an early clinical stage; NRG-GY026 tests trastuzumab.
Shares DESTINY-PanTumor02, Uterine carcinosarcoma, p53-abnormal endometrial cancer, including uterine serous carcinoma, Trastuzumab deruxtecan.
Shares DESTINY-PanTumor02, Trastuzumab deruxtecan, HER2.
Shares Endometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP), Uterine carcinosarcoma, p53-abnormal endometrial cancer, including uterine serous carcinoma, TP53.
Shares DESTINY-PanTumor02, Trastuzumab deruxtecan, HER2.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Trastuzumab deruxtecan, Endometrial cancer.
Shares Uterine carcinosarcoma, p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Trastuzumab.